Metformin, statins not associated with ovarian cancer

Share this content:
Ovarian cancer incidence was unrelated to metformin or statin usage among women with type 2 diabetes.
Ovarian cancer incidence was unrelated to metformin or statin usage among women with type 2 diabetes.

(HealthDay News) — In women with type 2 diabetes, no evidence was found of an association between the use of metformin or statins and the incidence of ovarian cancer, according to a study published online Feb. 7 in BJOG: An International Journal of Obstetrics and Gynaecology.

Elina Urpilainen, from the University of Oulu in Finland, and colleagues used national registers to identify 137,643 women (>40 years old) diagnosed with type 2 diabetes in Finland from 1996 through 2011.

The researchers found that 303 women were diagnosed with ovarian cancer during the follow-up period. Metformin was not associated with the incidence of ovarian cancer (hazard ratio, 1.02) compared to other oral antidiabetic medications. There was also no association noted between ovarian cancer incidence and statins (hazard ratio, 0.99).

"No evidence of an association between the use of metformin or statins and the incidence of ovarian cancer in patients with type 2 diabetes was found," the authors write.

Reference

  1. Urpilainen E, Marttila M, Hautakoski A, et al. The role of metformin and statins in the incidence of epithelial ovarian cancer in type 2 diabetes: A cohort and nested case-control study. BJOG: Int J Obstet Gy. 2018 Feb 7. doi:10.1111/1471-0528.15151
You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters